Netherlands Respiratory Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The Netherlands respiratory devices market operates within the wider European respiratory care devices industry, which is valued at USD 5.97 billion in 2025. The sector includes ventilators, nebulizers, continuous positive airway pressure (CPAP) devices, respiratory masks, and diagnostic equipment used in both clinical and homecare settings. Dutch healthcare spending reached EUR 120.2 billion in 2025, with EUR 11.7 billion allocated to medicines and medical devices, providing a supportive financial backdrop for respiratory device adoption.

• •European respiratory care devices market valued at USD 5.97 billion in 2025, projected to advance at a CAGR of 7.2-7.4% through 2031-2033
• •The Netherlands specifically is forecasted to register a higher CAGR of 9.60% from 2025 to 2030, outpacing the broader European average
• •Total Dutch medical device market estimated at approximately EUR 3.2 billion in 2025, growing at a projected 5.5% CAGR through 2030

The rising global and European burden of chronic respiratory diseases, including COPD, asthma, and obstructive sleep apnea, is the primary catalyst for market expansion. An aging demographic across Europe and the Netherlands, combined with increasing pollution-related respiratory ailments, continues to elevate demand for both diagnostic and therapeutic respiratory devices. Hospital infrastructure development, coupled with a shift toward home-based respiratory care, is further accelerating adoption rates.

• •Increasing prevalence of chronic respiratory diseases driven by aging populations and environmental factors across Europe
• •Growing adoption of home-based respiratory care solutions supported by reimbursement policies and patient preference
• •Technological advancements in portable and minimally invasive respiratory devices expanding clinical and consumer applications

The European respiratory devices market is segmented by product type, including therapeutic devices such as ventilators, CPAP devices, and nebulizers, as well as diagnostic devices like spirometers and pulse oximeters. Disease indication segmentation covers COPD, asthma, sleep apnea, and infectious respiratory conditions. Europe remains a strategically vital region for manufacturers due to its substantial chronic disease burden and well-established healthcare systems enabling widespread device adoption.

• •Product segments include therapeutic devices (ventilators, CPAP/BiPAP, nebulizers) and diagnostic devices (spirometers, capnographs, pulse oximeters)
• •Key disease indications driving demand are COPD, asthma, obstructive sleep apnea syndrome, and respiratory infections
• •The Netherlands serves as a key distribution and market-access gateway for respiratory device companies operating across the broader European Union

What are the recent trends and outlook?

The outlook for the Netherlands and European respiratory devices market remains strongly positive through 2030, driven by persistent disease burden, healthcare investment, and evolving care delivery models toward decentralized and home-based settings. Digital health integration, telemonitoring, and connected respiratory devices are emerging as significant growth areas. Manufacturers are increasingly focusing on patient-centric, portable, and smart-enabled respiratory solutions to capture the expanding market opportunity across both clinical and consumer segments.

• •European respiratory care market forecast to reach approximately USD 7.6-7.8 billion by 2031 at a sustained CAGR of 7.2-7.4%, with the Netherlands outpacing the regional average at 9.60%
• •Integration of connected health technologies and remote patient monitoring is reshaping respiratory care delivery models across Europe
• •Shift toward home-based respiratory therapy and portable devices represents a key structural trend influencing product development strategies